Anti-GDF-15 Antibody Neutralization for Cachexia-Related Muscle Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for effective therapeutic agents to treat cachexia and sarcopenia, particularly those targeting GDF15, which are associated with various diseases and result in involuntary muscle and weight loss, and current treatments are inadequate.
Innovation Solution
Development of a family of antibodies that specifically bind human GDF15, engineered to minimize immune response, inhibiting its activity and preventing muscle loss, and potentially administered with Fc-rhGDF15 fusion proteins to establish a steady-state plasma level.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies against GDF15 are used as therapeutic agents, then cachexia and sarcopenia can be treated by inhibiting muscle loss, but the development and production of these antibodies is complex and time-consuming
Solution Approach 1:
The patent applies preliminary action by pre-characterizing and pre-selecting antibody candidates with desired properties (binding affinity, neutralization capability, lack of cross-reactivity) before full-scale production. The antibodies are engineered and tested in advance to ensure therapeutic effectiveness, allowing for streamlined production and faster deployment of the therapeutic agent.
2Object-affected harmful factors
If antibodies are engineered to minimize immune response in human patients, then therapeutic safety is improved, but the engineering and optimization process becomes more complex
Solution Approach 1:
The patent applies parameter changes by systematically modifying antibody parameters such as amino acid sequences, glycosylation patterns, and structural configurations to optimize the balance between therapeutic effectiveness and immunogenicity. By adjusting these parameters, the antibodies are engineered to minimize harmful immune responses while maintaining their ability to inhibit GDF15 and prevent muscle loss.
3Quantity of substance
If GDF15 is targeted to treat cachexia and sarcopenia, then muscle mass and weight can be maintained, but the mechanism of action and optimal dosing remains to be fully determined
Solution Approach 1:
The patent applies feedback by establishing monitoring parameters and evaluation criteria that allow for real-time assessment of antibody efficacy and safety in patients. By collecting and analyzing feedback data on muscle mass changes, weight loss prevention, and immune responses, the optimal dosing regimen can be refined and adjusted to achieve the desired therapeutic effect while minimizing adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit muscle and weight loss in diseases such as cancer and chronic conditions, reversing cachexia and sarcopenia by maintaining muscle mass and weight, and can also be used to treat obesity.
Implementation Method 1
The antibodies contain hGDF15 binding sites based on the CDRs of the antibodies
Implementation Method 2
The disclosed antibodies prevent or inhibit the activity of (i.e., neutralize) hGDF15
Data Source
AI summary
Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.